Contact
searchSearch
HMP Global
Login

Sarcoma Specialty Channel

FDA Approval
FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors
09/13/2024
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US...
09/13/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
News
Selinexor Improves PFS, Time to Next Treatment in Metastatic, Advanced Dedifferentiated Liposarcoma
06/02/2022
Second-line or later treatment with selinexor for metastatic, advanced dedifferentiated liposarcoma was associated with longer PFS and time to next treatment compared to placebo.
Second-line or later treatment with selinexor for metastatic, advanced dedifferentiated liposarcoma was associated with longer PFS and time to next treatment compared to placebo.
Second-line or later treatment...
06/02/2022
Oncology
Test Your Knowledge
Quiz: Do Randomized Trials With QoL Assessment Achieve A Clinical Benefit?
09/14/2021
True or false: In the treatment of advanced STS, randomized trials with QoL assessment were more likely to achieve the ESMO-Magnitude of Clinical Benefit Scale substantial benefit threshold.
True or false: In the treatment of advanced STS, randomized trials with QoL assessment were more likely to achieve the ESMO-Magnitude of Clinical Benefit Scale substantial benefit threshold.
True or false: In the treatment...
09/14/2021
Oncology
Conference Coverage
Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape
09/14/2021
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was...
09/14/2021
Oncology
Test Your Knowledge
Quiz: FDA Approves First Treatment Option for Kaposi Sarcoma in How Many Years?
11/09/2020
True or false: The FDA recently approved the first new AIDS-related Kaposi sarcoma treatment in 6 years.
True or false: The FDA recently approved the first new AIDS-related Kaposi sarcoma treatment in 6 years.
True or false: The FDA recently...
11/09/2020
Oncology
News
FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors
10/26/2020
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS...
10/26/2020
Oncology
Podcasts
Episode 4: Evolving Therapies for Ewing Sarcoma
10/15/2020
In the fourth episode, Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, discuss recent trial data and evolving therapies for treatment of Ewing sarcoma.
In the fourth episode, Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, discuss recent trial data and evolving therapies for treatment of Ewing sarcoma.
In the fourth episode, Brian Van...
10/15/2020
Oncology
Episode 3: Standard of Care Treatment for Ewing Sarcoma
Podcasts
Episode 3: Standard of Care Treatment for Ewing Sarcoma
09/24/2020
Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, discuss recent data comparing the American Standard versus European Standard for treatment of Ewing sarcoma.
Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, discuss recent data comparing the American Standard versus European Standard for treatment of Ewing sarcoma.
Brian Van Tine, MD, PhD, and...
09/24/2020
Oncology
News
Doxorubicin–Pembrolizumab Combo Shows Promise in Advanced Anthracycline-Naïve Sarcoma
09/23/2020
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
Doxorubicin combined with...
09/23/2020
Oncology
Test Your Knowledge
Quiz: Which of These Agents Yielded Durable Responses in Patients With Epithelioid Sarcoma?
08/13/2020
In a large clinical study, which of the following agents yielded durable responses in patients with epithelioid sarcoma?
In a large clinical study, which of the following agents yielded durable responses in patients with epithelioid sarcoma?
In a large clinical study, which...
08/13/2020
Oncology

News

FDA Approval
FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors
09/13/2024
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US...
09/13/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
News
Selinexor Improves PFS, Time to Next Treatment in Metastatic, Advanced Dedifferentiated Liposarcoma
06/02/2022
Second-line or later treatment with selinexor for metastatic, advanced dedifferentiated liposarcoma was associated with longer PFS and time to next treatment compared to placebo.
Second-line or later treatment with selinexor for metastatic, advanced dedifferentiated liposarcoma was associated with longer PFS and time to next treatment compared to placebo.
Second-line or later treatment...
06/02/2022
Oncology
Conference Coverage
Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape
09/14/2021
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was...
09/14/2021
Oncology
News
FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors
10/26/2020
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS...
10/26/2020
Oncology
News
Doxorubicin–Pembrolizumab Combo Shows Promise in Advanced Anthracycline-Naïve Sarcoma
09/23/2020
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
Doxorubicin combined with...
09/23/2020
Oncology
News
Maintenance Cyclophosphamide Plus Celecoxib Feasible for Metastatic Ewing Sarcoma
05/31/2020
A maintenance therapy regimen comprising oral cyclophosphamide plus celecoxib has demonstrated feasibility in patients with metastatic Ewing sarcoma.
A maintenance therapy regimen comprising oral cyclophosphamide plus celecoxib has demonstrated feasibility in patients with metastatic Ewing sarcoma.
A maintenance therapy regimen...
05/31/2020
Oncology
News
FDA Approves Pomalidomide for Certain Adults With Kaposi Sarcoma
05/15/2020
The FDA has approved pomalidomide for use in adults with AIDS-related Kaposi sarcoma unresponsive to antiretroviral therapy and Kaposi sarcoma in HIV-negative adults.
The FDA has approved pomalidomide for use in adults with AIDS-related Kaposi sarcoma unresponsive to antiretroviral therapy and Kaposi sarcoma in HIV-negative adults.
The FDA has approved...
05/15/2020
Oncology
News
High Frequency of Pathogenic Germline Variants Observed in Patients With Osteosarcoma
05/06/2020
Germline genetic testing may be warranted for patients with osteosarcoma, according to findings from a study by Lisa Mirabello, PhD, et al.
Germline genetic testing may be warranted for patients with osteosarcoma, according to findings from a study by Lisa Mirabello, PhD, et al.
Germline genetic testing may be...
05/06/2020
Oncology
News
No OS Benefit in Adding Olaratumab to Doxorubicin for Advanced STS
04/29/2020
Adding olaratumab to doxorubicin in patients with advanced STS did not significantly improve OS in the ANNOUNCE clinical trial.
Adding olaratumab to doxorubicin in patients with advanced STS did not significantly improve OS in the ANNOUNCE clinical trial.
Adding olaratumab to doxorubicin...
04/29/2020
Oncology

Interactive Features

Test Your Knowledge
Quiz: Do Randomized Trials With QoL Assessment Achieve A Clinical Benefit?
09/14/2021
True or false: In the treatment of advanced STS, randomized trials with QoL assessment were more likely to achieve the ESMO-Magnitude of Clinical Benefit Scale substantial benefit threshold.
True or false: In the treatment of advanced STS, randomized trials with QoL assessment were more likely to achieve the ESMO-Magnitude of Clinical Benefit Scale substantial benefit threshold.
True or false: In the treatment...
09/14/2021
Oncology
Test Your Knowledge
Quiz: FDA Approves First Treatment Option for Kaposi Sarcoma in How Many Years?
11/09/2020
True or false: The FDA recently approved the first new AIDS-related Kaposi sarcoma treatment in 6 years.
True or false: The FDA recently approved the first new AIDS-related Kaposi sarcoma treatment in 6 years.
True or false: The FDA recently...
11/09/2020
Oncology
Test Your Knowledge
Quiz: Which of These Agents Yielded Durable Responses in Patients With Epithelioid Sarcoma?
08/13/2020
In a large clinical study, which of the following agents yielded durable responses in patients with epithelioid sarcoma?
In a large clinical study, which of the following agents yielded durable responses in patients with epithelioid sarcoma?
In a large clinical study, which...
08/13/2020
Oncology
Test Your Knowledge
Quiz: Is Surgical Resection a Primary Therapy Option for TGCT?
08/11/2020
True or False: Radiotherapy is no longer a primary therapy option in most tertiary tumor centers, while surgical resection, either open or arthroscopic, is.
True or False: Radiotherapy is no longer a primary therapy option in most tertiary tumor centers, while surgical resection, either open or arthroscopic, is.
True or False: Radiotherapy is...
08/11/2020
Oncology
Test Your Knowledge
Quiz: Is Cabozantinib a Potential New Therapy Option for Ewing Sarcoma, Osteosarcoma?
07/20/2020
True or False: Cabozantinib has shown anti-tumor activity in patients with advanced Ewing sarcoma and osteosarcoma.
True or False: Cabozantinib has shown anti-tumor activity in patients with advanced Ewing sarcoma and osteosarcoma.
True or False: Cabozantinib has...
07/20/2020
Oncology
Test Your Knowledge
Quiz: Types of Tenosynovial Giant Cell Tumors
01/10/2020
What are the 2 types of tenosynovial giant cell tumors?
What are the 2 types of tenosynovial giant cell tumors?
What are the 2 types of...
01/10/2020
Oncology
Test Your Knowledge
Quiz: Which Joints Do Tenosynovial Giant Cell Tumors Affect?
01/06/2020
True or False: Almost any joint in the body can be affected by tenosynovial giant cell tumors.
True or False: Almost any joint in the body can be affected by tenosynovial giant cell tumors.
True or False: Almost any joint...
01/06/2020
Oncology
Test Your Knowledge
Quiz: Use of DCC-3014 for Diffuse-Type TGCT
12/18/2019
Findings from a phase 1 trial show that DCC-3014 is ______ in patients with diffuse-type TGCT.
Findings from a phase 1 trial show that DCC-3014 is ______ in patients with diffuse-type TGCT.
Findings from a phase 1 trial...
12/18/2019
Oncology
Test Your Knowledge
Quiz: Traditional Management of TGCT
12/18/2019
True or False: Historically, TGCT has been managed by multiple surgical resections, including joint replacement therapy and (even in rare cases) amputation.
True or False: Historically, TGCT has been managed by multiple surgical resections, including joint replacement therapy and (even in rare cases) amputation.
True or False: Historically,...
12/18/2019
Oncology
Test Your Knowledge
Quiz: Is Pazopanib a Therapy Option for Extraskeletal Myxoid Chondrosarcoma?
10/01/2019
True or False: Pazopanib may be a suitable therapy option for patients with progressive and advanced extraskeletal myxoid chondrosarcoma who do not respond to first-line anthracycline-based chemo.
True or False: Pazopanib may be a suitable therapy option for patients with progressive and advanced extraskeletal myxoid chondrosarcoma who do not respond to first-line anthracycline-based chemo.
True or False: Pazopanib may be...
10/01/2019
Oncology

Recent News

FDA Approval
FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors
09/13/2024
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US...
09/13/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
News
Selinexor Improves PFS, Time to Next Treatment in Metastatic, Advanced Dedifferentiated Liposarcoma
06/02/2022
Second-line or later treatment with selinexor for metastatic, advanced dedifferentiated liposarcoma was associated with longer PFS and time to next treatment compared to placebo.
Second-line or later treatment with selinexor for metastatic, advanced dedifferentiated liposarcoma was associated with longer PFS and time to next treatment compared to placebo.
Second-line or later treatment...
06/02/2022
Oncology
Conference Coverage
Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape
09/14/2021
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was...
09/14/2021
Oncology
News
FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors
10/26/2020
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS...
10/26/2020
Oncology
News
Doxorubicin–Pembrolizumab Combo Shows Promise in Advanced Anthracycline-Naïve Sarcoma
09/23/2020
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
Doxorubicin combined with...
09/23/2020
Oncology
News
Maintenance Cyclophosphamide Plus Celecoxib Feasible for Metastatic Ewing Sarcoma
05/31/2020
A maintenance therapy regimen comprising oral cyclophosphamide plus celecoxib has demonstrated feasibility in patients with metastatic Ewing sarcoma.
A maintenance therapy regimen comprising oral cyclophosphamide plus celecoxib has demonstrated feasibility in patients with metastatic Ewing sarcoma.
A maintenance therapy regimen...
05/31/2020
Oncology
News
FDA Approves Pomalidomide for Certain Adults With Kaposi Sarcoma
05/15/2020
The FDA has approved pomalidomide for use in adults with AIDS-related Kaposi sarcoma unresponsive to antiretroviral therapy and Kaposi sarcoma in HIV-negative adults.
The FDA has approved pomalidomide for use in adults with AIDS-related Kaposi sarcoma unresponsive to antiretroviral therapy and Kaposi sarcoma in HIV-negative adults.
The FDA has approved...
05/15/2020
Oncology
News
High Frequency of Pathogenic Germline Variants Observed in Patients With Osteosarcoma
05/06/2020
Germline genetic testing may be warranted for patients with osteosarcoma, according to findings from a study by Lisa Mirabello, PhD, et al.
Germline genetic testing may be warranted for patients with osteosarcoma, according to findings from a study by Lisa Mirabello, PhD, et al.
Germline genetic testing may be...
05/06/2020
Oncology
News
No OS Benefit in Adding Olaratumab to Doxorubicin for Advanced STS
04/29/2020
Adding olaratumab to doxorubicin in patients with advanced STS did not significantly improve OS in the ANNOUNCE clinical trial.
Adding olaratumab to doxorubicin in patients with advanced STS did not significantly improve OS in the ANNOUNCE clinical trial.
Adding olaratumab to doxorubicin...
04/29/2020
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use